
    
      The protocol specifies rules for dose-limiting toxicity and a maximum tolerated dose (MTD).
      To gain further experience with the MTD, and/or at some lower optimal biologic dose level, an
      expansion cohort (Part B) enrolled patients with metastatic urothelial carcinoma with
      fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 genetic alterations.
    
  